Tom 13, Nr 6 (2018)
Artykuł przeglądowy
Opublikowany online: 2019-02-13
Wyświetlenia strony
1033
Wyświetlenia/pobrania artykułu
1373
Stanowisko grupy ekspertów dotyczące miejsca iwabradyny w optymalizacji terapii u chorych z przewlekłą niewydolnością serca
DOI: 10.5603/FC.2018.0120
Folia Cardiologica 2018;13(6):534-544.
Streszczenie
Przyspieszona częstość rytmu serca stanowi czynnik ryzyka śmiertelności ogólnej oraz sercowo-naczyniowej w różnych
populacjach pacjentów. Stosowanie klasycznych leków zwalniających rytm serca, takich jak beta-adrenolityki czy antagoniści
wapnia z grupy niedihydropirydynowych (werapamil i diltiazem), jest często ograniczone z powodu ich działań
niepożądanych. Iwabradyna jest unikatowym, nowoczesnym lekiem, którego mechanizm działania polega na blokowaniu
prądu If w węźle zatokowo-przedsionkowym. Przekłada się to na zmniejszenie częstości rytmu serca — parametru związanego
z niekorzystnym rokowaniem u pacjentów z niewydolnością serca (HF). Niniejszy dokument stanowi opinię grupy
ekspertów będącą podsumowaniem aktualnej wiedzy dotyczącej iwabradyny i jej zastosowania w populacji chorych z HF.
Słowa kluczowe: optymalizacja terapiiniewydolność sercaiwabradyn
Referencje
- Czech M, Opolski G, Zdrojewski T, et al. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013; 71(3): 224–232.
- Heidenreich PA, Albert NM, Allen LA, et al. American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013; 6(3): 606–619.
- McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33(14): 1787–1847.
- Wożakowska-Kapłon B, Mamcarz A, Filipiak KJ. Iwabradyna w terapii niewydolności serca — od teorii do praktyki. Medical Education, Warszawa 2014.
- Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004; 25(18): 1614–1619.
- Rywik TM, Koziarek J, Piotrowski W, et al. Trends in heart failure mortality in Poland between 1980 and 2010. Pol Arch Med Wewn. 2013; 123(12): 664–671.
- Gierczyński J, Gryglewicz J, Karczewicz E, Zalewska H. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Instytut Zarządzania w ochronie zdrowia 2013. http://niewydolnosc-serca pl/ns_raport2013.pdf (4.12.2018).
- http://apps who int/medicinedocs/documents/s22177en/s22177en.pdf. OECD 2015 Avoidable hospital admissions in Health at a Glance 2015: OECD Indicators, OECD Publishing, Paris. (06.12.2018).
- Maron BJ, Towbin J, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006; 113(14): 1807–1816.
- McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150(11): 784–794.
- Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69(1): 24–31.
- Jankowska E, Ponikowski P. Prevalence of high resting heart rate in the contemporary population of patients with systolic heart failure in real life: the results from DATA-HELP. Heart Failure, Belgrad, 2012.
- Kasprzak JD, Stępińska J, Wożakowska-Kapłon B, et al. Optymalna częstość rytmu serca — aktualny cel terapii kardiologicznej. Stanowisko grupy ekspertów Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2012; 70(10): 1081–1094.
- Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
- DeVore AD, Mi X, Mentz RJ, et al. Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. Am Heart J. 2016; 173: 172–178.
- Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008; 102(11): 1524–1529.
- Opolski G, Ozierański K, Lelonek M, et al. Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med. 2017; 127(10): 657–665.
- DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004; 64(16): 1757–1765.
- Accili EA, Proenza C, Baruscotti M, et al. From funny current to HCN channels: 20 years of excitation. News Physiol Sci. 2002; 17: 32–37.
- DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature. 1991; 351(6322): 145–147.
- DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Ann Rev Physiol. 1993; 55: 455–472.
- Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002; 120(1): 1–13.
- Charakterystyka produktu leczniczego Ivohart 5 mg; 7,5 mg, tabletki powlekanie 12.05.2018.
- Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol. 1997; 339(1): 43–51.
- Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995; 275(2): 659–666.
- Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002; 282(2): H672–H679.
- Berdeaux A. Preclinical results with I(f) current inhibition by ivabradine. Drugs. 2007; 67(Suppl 2): 25–33.
- De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008; 10(6): 550–555.
- Borer JS, Fox K, Jaillon P, et al. Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003; 107(6): 817–823.
- Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–885.
- Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010; 12(1): 75–81.
- Ponikowski P, Voors A, Anker S, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 74(10): 1037–1147.
- Ferrari R, Ford I, Fox K, et al. Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology. 2008; 110(4): 271–282.
- Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372(9641): 817–821.
- Tardif JC, Ponikowski P, Kahan T, et al. ASSOCIATE Investigators. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013; 168(2): 789–794.
- Tardif JC, O'Meara E, Komajda M, et al. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32(20): 2507–2515.
- Fox K, Ford I, Steg P, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371(12): 1091–1099.
- Hidalgo FJ. Early therapy with beta blockers plus ivabradine versus beta blockers alone in patients hospitalised with heart failure and reduced ejection fraction (ETHIC-AHF Study): results at one-year follow-Up. Int J Clin Cardiol. 2017; 4(1).
